Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer

European Urology

Volumn 47, Issue 1, 2005, Pages 16-21

  Klotz, Laurence ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Active surveillance; Prostate cancer; PSA doubling time

Indexed keywords

ANDROGEN; ANTIANDROGEN; BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CLINICAL TRIAL; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; URETER OBSTRUCTION;

HUMANS; MALE; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 9644270344     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.09.010     Document Type: Review

References (30)

1. J.E. Johansson, H.O. Adami, and S.O. Andersson High 10 year survival rate in patients with early, untreated prostatic cancer JAMA 267 1992 2191 2196
2. J.E. Johansson, L. Holmberg, and 5 Johansson Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden JAMA 277 1997 467 471
3. K.A. Hanash, D.C. Utz, and E.N. Cook Carcinoma of the prostate: a 15 year followup J Urol 107 1972 450 453
4. G.B. Cook, and F.R. Watson Twenty nodules of prostate cancer not treated by total prostatecotmy J Urol 100 1968 672 674
5. R. Barnes, A. Hirst, and R. Rosenquist Early carcinoma of the prostate: comparison of stages A and B J Urol 115 1976 404 405
6. S.P. Lerner, C. Seale-Hawkins, and C.E. Carlton The risk of dying of prostate cancer in patients with clinically localized disease J Urol 146 1991 1040 1045
7. R. Handley, T.W. Carr, and D. Travis Deferred treatment for prostate cancer Br I Urol 62 1988 249 253
8. J. Adolfsson, J. Carstensen, and T. Lowhagen Deferred treatment in clinically localized prostate carcinoma Brit J Urol 69 1992 183 187
9. G. Waaler, and A.E. Stenwig Prognosis of localised prostatic cancer managed by "Watch and Wait" policy Br I Urol 72 1993 214 219
10. W.F. Whitmore, I.A. Warner, and I.M. Thompson Expectant management of localized prostatic cancer Cancer 67 1991 1091 1096
11. N.J.R. George Natural history of localised prostatic cancer managed by conservative therapy alone Lancet 1 1988 494 496
12. G. Aus, I. Hugosson, and L. Norlen Long-term survival and mortality in prostate cancer treated with noncurative intent J Urol 154 1995 460 465
13. G. Sandblom, and M. Dufmats Varenhorst Long-term survival in a Swedish population-based cohort of men with prostate cancer Urology 56 3 2000 442 447
14. P.O. Madsen, P.H. Graversen, T.C. Gasser, and D.K. Corle Treatment of localized prostatic cancer. Radical prostatectomy versus placebo. A 15-year follow-up Scand J Urol Nephrol Suppl 110 1988 95 100
15. P.C. Albertsen, I.A. Hanley, D.F. Gleason, and M.J. Barry Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 1998 975 980
16. Albertsen PC. Prostate cancer mortality trends in Oregon and Connecticut. Presented at the Whistler International Conference on Prostate Cancer, March 2001.
17. G.W. Chodak The management of localized prostate cancer J Urol 152 5 Pt 2 1994 1766
18. W.A. Sakr, G.P. Haas, B.F. Cassin, J.E. Pontes, and J.D. Crissman The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients J Urol 150 2 Pt 1 1993 379 385
19. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 17 1999 1591 1597
20. M.W. Kattan, M.J. Zelefsky, P.A. Kupelian, P.T. Scardino, and Z. Fuks Leibel SA.Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 19 2000 3352 3359
21. A.L. Zeitman, H. Thakral, L. Wilson, and P. Schellhammer Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy J Urol 166 5 2001 1702 1706
22. R. Choo, G. DeBoer, L. Klotz, C. Danjoux, G.C. Morton, and E. Rakovitch PSA doubling time of prostate carcinoma managed with watchful observation alone Int J Radiat Oncol Biol Phys 50 3 2001 615 620
23. R. Choo, L. Klotz, C. Danjoux, and G. Morton Feasibility study of watchful waiting for localized low to intermediate greade prostate cancer with selective delayed intervention based on PSA, histologic, and/or clinical progression J Urol 167 2002 1664 1669
24. V. Do, R. Choo, G. De Boer, L. Klotz, C. Danjoux, and G. Morton The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer BJU Int 89 7 2002 703 709
25. L. Holmberg, A. Bill-Axelson, F. Helgesen, J.O. Salo, P. Folmerz, and M. Haggman A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer N Engl J Med 347 11 2002 781 789
26. G. Lu Yao, and P. Albertsen Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut BMJ 325 7367 2002 740
27. J. Epstein, P. Walsh, and H.B. Carter Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease J Urol 166 5 2001 1688 1691
28. W. Sakr Prevalence of invasive prostate cancer in men dying of trauma Eur Urol 30 1996 138
29. I.C. Sawczuk, and Shabsigh Cancer of the Prostate: Incidence in the USA J. Mylo C. Godec In Prostate Cancer: Science and Clinical Practice 2003 Academic Publishers London 115 120
30. I.M. Thompson, P.J. Goodman, C.M. Tangen, M.S. Lucia, G.J. Miller, and L.G. Ford The influence of finasteride on the development of prostate cancer N Engl J Med 349 3 2003 215 224